Accessibility help Skip to navigation Skip to content Skip to footer
  • Sign In
  • Subscribe
Open drawer menu Open search bar
Financial Times
myFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
    Most Read
    • Emmanuel Macron dashes Boris Johnson’s hope for Brexit deal
    • Is business right to still fear a no-deal Brexit?
    • The next stop on Donald Trump’s end-of-diplomacy tour
    • Hong Kong’s ‘Gang of Four’ hits back at Beijing 
    • Did Angela Merkel really offer a big Brexit concession?
  • US
    Sections
    • US Home
    • US Economy
    • US Politics & Policy
    • US Companies
    Most Read
    • Yield curve inverts after hawkish Fed remarks
    • The next stop on Donald Trump’s end-of-diplomacy tour
    • Macron says G7 will not issue joint communiqué to avoid row among leaders
    • So you want to buy Greenland, Mr Trump? Let’s talk terms
    • Private equity: the generational feud that rocked Apollo
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Burford executive accused of trading documents for sex tape
    • HSBC urges peaceful resolution to Hong Kong protests
    • Hasbro to buy ‘Peppa Pig’ owner Entertainment One for £3.3bn
    • Russia to launch floating nuclear reactor
    • Asahi’s voracious thirst sees it take crown as king of M&A in Asia
  • Tech
  • Markets
    Sections
    • Markets Home
    • fastFT
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    Most Read
    • Yield curve inverts after hawkish Fed remarks
    • Righteous anger from the US will not win the tech war with China
    • Sterling rises on optimistic Merkel comments
    • Falling cost of debt piles pressure on governments to spend more
    • Fears grow that softer Volcker rule will stoke Wall Street risk
  • Graphics
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Instant Insight
    • Lex
    • Alphaville
    • Obituaries
    • Letters
    Most Read
    • The next stop on Donald Trump’s end-of-diplomacy tour
    • Six ways to manage money — and not fall out with your partner
    • So you want to buy Greenland, Mr Trump? Let’s talk terms
    • Don’t forget the other half of German history
    • Righteous anger from the US will not win the tech war with China
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    Most Read
    • My experiment in studying science has reinforced my belief in exams
    • Why so many senior women are unfairly judged at work
    • Creative summer: visiting an art gallery
    • Beware the dead hand of the controlling founder
    • The plague of long-running feuds in family businesses
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Next Act
    • Style
    • Travel
    Most Read
    • Putin and the Patriarchs: how geopolitics tore apart the Orthodox church
    • Six ways to manage money — and not fall out with your partner
    • Don’t forget the other half of German history
    • Ivory towers: the rise of luxury student lodgings
    • The trouble with American tourism
  • How to Spend It
  • Sign In
  • Subscribe
Menu Search
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Graphics
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
  • Sign In
  • Subscribe

Get a fresh start.

Get a fresh start.
Choose your FT trial

Hannah Kuchler

US pharma and biotech correspondent
Hannah Kuchler reports on pharma, biotech and healthcare. After covering Silicon Valley for over five years, she's now focusing on how technology is transforming our health.
Email Hannah Kuchler @hannahkuchler (link opens in a new browser window)
Email Hannah Kuchler @hannahkuchler (link opens in a new browser window)

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Wednesday, 21 August, 2019
    Gilead Sciences Inc
    Gilead to challenge US patents on HIV drug Truvada

    Move comes amid increasing scrutiny of drugmaker over pricing practices

  • Wednesday, 21 August, 2019
    Health Care
    Powell Jobs-backed start-up to offer ‘genetic counselling’

    US government hires Color to provide human touch in massive health data research project

  • Monday, 19 August, 2019
    Novartis AG
    Novartis executive sold $1m shares ahead of probe

    Company faces possible civil or criminal charges over manipulated Zolgensma data

  • Sunday, 18 August, 2019
    Drug prices
    Gilead did not seek US exclusivity on PrEP with Truvada

    Drugmaker could be liable for billions in royalties to US government

  • Wednesday, 14 August, 2019
    Novartis AG
    Novartis ousted scientists before reporting data manipulation

    US regulator investigates timing of revelation about studies behind world’s most expensive drug

  • Sunday, 11 August, 2019
    Drug prices
    US patients struggle to obtain Eli Lilly’s half-price insulin

    Cheaper option was unveiled shortly before company was grilled by Congress about soaring prices

  • Wednesday, 7 August, 2019
    Teva Pharmaceutical Industries Ltd
    Pending litigation weighs on Teva

    Drugmaker’s earnings better than expected but investors nervous about potential liabilities

  • Tuesday, 6 August, 2019
    Novartis AG
    FDA probing ‘data manipulation’ from early tests of Novartis drug

    Company could face civil or criminal penalties over issue related to world’s priciest drug

  • Wednesday, 31 July, 2019
    US opioid epidemic
    Arizona brings case against Purdue owners in Supreme Court

    State tries unusual legal move over alleged ‘massive cash transfers’ to Sackler family members

  • Promoted Content
  • Wednesday, 31 July, 2019
    Drug prices
    Trump unveils plan to legalise medicine imports from Canada

    Move comes as drug prices become a focus of 2020 presidential campaign

  • Tuesday, 30 July, 2019
    Gilead Sciences Inc
    Gilead lifts full-year revenue guidance as HIV drug sales rise
  • Tuesday, 30 July, 2019
    Amgen Inc
    Amgen boosts earnings guidance amid optimism for new cancer treatment
  • Tuesday, 30 July, 2019
    Merck & Co Inc
    Merck raises forecasts as cancer drug sales soar

    Sales rose 12 per cent driven by a rise in revenue from tumour treatment Keytruda

  • Tuesday, 30 July, 2019
    Leveraged loans
    Dim prognosis for US healthcare as politicians target billing

    Moves to shield patients from unexpected treatment costs leave debt investors nervous

  • Monday, 29 July, 2019
    Pfizer Inc
    Pfizer and Mylan to combine off-patent drugs businesses

    All-stock deal will create pharma group expected to generate $20bn in revenues

  • Saturday, 27 July, 2019
    Pfizer Inc
    Pfizer and Mylan set to merge off-patent drugs operations

    Stock deal will create large seller of products including former blockbusters Lipitor and Viagra

  • Friday, 26 July, 2019
    AbbVie Inc
    AbbVie raises guidance as cancer treatments boost sales

    Chicago-based pharmaceutical company reported better than expected earnings and revenue

  • Thursday, 25 July, 2019
    Bristol-Myers Squibb Co
    Bristol-Myers Squibb trims earnings guidance on Celgene deal
  • Wednesday, 24 July, 2019
    Biotech
    Freenome raises $160m for early detection cancer tests

    US biotech preparing large scale trials of its liquid biopsies for bowel disease

  • Wednesday, 24 July, 2019
    Drugs research
    GSK market hopes boosted by two-drug HIV trial

    Dovato shown to be as effective as Gilead’s traditional combination treatment

  • Tuesday, 23 July, 2019
    Pharmaceuticals sector
    Drugmakers shell out record amount lobbying Congress

    Industry groups and companies ramp up spending as US pricing debate gets under way

  • Tuesday, 23 July, 2019
    Biogen Idec Inc
    Biotech group Biogen boosted by sales of key drugs

    Treatments for multiple sclerosis and spinal muscular atrophy help Biogen beat forecasts

  • Tuesday, 23 July, 2019
    ExplainerDrug prices
    Can Donald Trump lower drug prices?

    President’s efforts to reduce high cost of pharmaceuticals for patients have so far failed

  • Friday, 19 July, 2019
    Digital health
    Google’s sister company creates smart nappies

    Verily and Pampers say Lumi nappies will track when babies sleep, wee and poo

  • Tuesday, 16 July, 2019
    Johnson & Johnson Co Inc
    J&J boosts outlook as strong overseas sales lift results

    US healthcare group also reported a decline in litigation expenses

Previous You are on page 1 Next

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Manage cookies
Accept & continue

Useful links

Support

View Site Tips Help Centre About Us Accessibility myFT Tour Careers

Legal & Privacy

Terms & Conditions Privacy Cookies Copyright Slavery Statement & Policies

Services

FT Live Share News Tips Securely Individual Subscriptions Group Subscriptions Republishing Contracts & Tenders
Executive Job Search Advertise with the FT Follow the FT on Twitter FT Transact Secondary Schools

Tools

Portfolio Today's Newspaper (ePaper) Alerts Hub MBA Rankings
Enterprise Tools News feed Newsletters Currency Converter
More from the FT Group
Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2019. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
  • US
    • US Economy
    • US Politics & Policy
    • US Companies
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • fastFT
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
  • Graphics
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Instant Insight
    • Lex
    • Alphaville
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Next Act
    • Style
    • Travel
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
  • Science
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • EM Squared
  • Lunch with the FT
  • FT Confidential Research
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In